The aim of the CF START trial is determine the safest and most effective way to treat infants diagnosed with Cystic Fibrosis (CF) with antibiotics. At the moment infants in the UK are prescribed an antibiotic, usually flucloxacillin, every day to prevent infection with a bacteria (bug) called Staphylococcus aureus (SA).

Although this approach appears to help prevent SA infection, there is a worry that it may make earlier infection with other bugs, such as Pseudomonas aeruginosa (PsA) more likely.

This trial is designed to test if infants with CF are more likely to get an earlier infection from PsA if they are taking flucloxacillin on a daily basis (“Prevent and Treat”) or Antibiotics in a more targeted manner (“Detect and Treat”).